Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Geschlossen

14.91 4.56

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.91

Max

15.17

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.4M -14M
EPS	-0.15
Angestellte	37
EBITDA	312K -12M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+112.08% upside

Dividenden
By Acuity
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-29M 1.3B
Vorheriger Eröffnungskurs	10.35
Vorheriger Schlusskurs	14.91

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Juli 2026, 23:51 UTC

Cryptocurrency Gains Amid Investor Shift from Gold, While Geopolitical Tensions and Economic Data Loom Over Financial Markets.

18. Juli 2026, 23:51 UTC

Bitcoin and Ethereum rise amid investor shift from gold, while geopolitical tensions and U.S. Treasury shifts signal potential market volatility ahead of key economic data releases.

18. Juli 2026, 23:51 UTC

Bitcoin and Ethereum rise as investors shift from gold amid market volatility, while U.S. labor participation hits a 50-year low and geopolitical tensions escalate in the Middle East.

18. Juli 2026, 23:51 UTC

Bitcoin and Ethereum gain momentum amid investor shift from gold, while geopolitical tensions and upcoming economic data influence market sentiment.

18. Juli 2026, 23:41 UTC

Canada's Retail Sales Ex Autos MoM report on July 23, 2026, forecasts modest growth at 0.4%, amid cautious market sentiment due to geopolitical tensions and economic uncertainties.

18. Juli 2026, 23:41 UTC

Chicago Fed National Activity Index Release on July 23, 2026, Expected to Reflect Economic Fluctuations Amid Geopolitical Tensions and Rising Oil Prices.

18. Juli 2026, 23:31 UTC

ECB Set to Raise Interest Rates Amid Rising Inflation Concerns Driven by Geopolitical Tensions on July 23, 2026.

18. Juli 2026, 23:31 UTC

Euro Area's Deposit Facility Rate Expected to Hold Steady at 2.25% Amid Geopolitical Tensions and Inflation Concerns

18. Juli 2026, 23:21 UTC

China's Loan Prime Rate (LPR) 1Y set for July 20, 2026 at a forecasted 0.03%, amid cautious investor sentiment and rising inflation concerns.

18. Juli 2026, 23:21 UTC

China's Loan Prime Rate Expected to Remain Steady at 3.50% for Five Years Amid Stable Market Sentiment

18. Juli 2026, 22:51 UTC

Japan's Inflation Rate YoY Release on July 23, 2026 Sparks Concerns Over Economic Pressures and Market Volatility Amid Rising Interest Rates.

18. Juli 2026, 22:51 UTC

Japan's Core Inflation Rate YoY Expected to Rise to 1.6% Amidst CFO Concerns Over Economic Pressures and Geopolitical Tensions

18. Juli 2026, 22:41 UTC

Mortgage Rates Hit Nine-Month High Amid Inflation Concerns and Cautious Market Sentiment Ahead of Upcoming Data Release.

18. Juli 2026, 22:41 UTC

Canada's Inflation Rate Expected to Drop Significantly Amid Geopolitical Tensions and Recent Price Declines

18. Juli 2026, 22:41 UTC

Canada's Inflation Rate Expected to Decline Slightly in June Amid Geopolitical Tensions and Volatile Market Conditions

18. Juli 2026, 22:41 UTC

Canada's Core Inflation Rate Release on July 20, 2026: Market Anticipates Lower Figures Amid Geopolitical Tensions and Recent CPI Drop.

18. Juli 2026, 22:31 UTC

Japan's June 2026 export growth forecasted at 0.186%, amid market volatility and geopolitical tensions impacting major exporters.

18. Juli 2026, 22:31 UTC

Japan's Balance of Trade report predicts a -120 billion yen deficit amid rising import costs and negative market sentiment, as stock indices decline due to global economic concerns.

18. Juli 2026, 22:31 UTC

Brazil's Central Bank to announce SELIC interest rate decision on July 20, 2026, amid stable market sentiment.

18. Juli 2026, 22:31 UTC

UK Consumer Confidence Expected to Decline to -21.0 Amid Rising Inflation and Geopolitical Tensions

18. Juli 2026, 22:21 UTC

Australia's S&P Global Services PMI Flash Release on July 23, 2026: Key Indicator Amid Mixed Market Sentiment and Inflation Concerns.

18. Juli 2026, 22:21 UTC

Optimism Grows Ahead of Australia's S&P Global Manufacturing PMI Flash Release Amid Strong Industrial Performance and Positive Investor Sentiment

18. Juli 2026, 22:11 UTC

Turkey's TCMB Expected to Maintain 37% Interest Rate Amid Inflation Pressures and Geopolitical Tensions on July 23, 2026.

18. Juli 2026, 22:01 UTC

South Korea's Q2 GDP Growth Rate Estimate Set for July 22 Amid Cautious Optimism and External Concerns.

18. Juli 2026, 22:01 UTC

South Korea's Upcoming GDP Growth Rate Release on July 22, 2026, Sparks Investor Anxiety Amid Geopolitical Tensions and Foreign Sell-Offs.

18. Juli 2026, 21:11 UTC

UK Factory Orders Forecasted at -40.0 Amid Mixed Sentiment and Economic Pressures Ahead of July 2026 Release

18. Juli 2026, 21:11 UTC

UK CBI Business Optimism Index for Q3 2026 set to reveal cautious optimism amid geopolitical tensions and inflationary pressures.

18. Juli 2026, 20:51 UTC

Correlated Moves

Macro News

Bitcoin is trading higher today amid rising geopolitical tensions and crude oil prices. Ethereum's movement reflects similar market dynamics in the cryptocurrency sector.

18. Juli 2026, 20:01 UTC

Macro News

Crude oil prices rose in after-market hours amid escalating geopolitical tensions affecting shipping routes, particularly following military actions involving Iran and U.S. forces.

18. Juli 2026, 20:01 UTC

API Crude Oil Stock Change Report Set for July 21, Amid Geopolitical Tensions Driving Price Volatility and Supply Concerns.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

112.08% Vorteil

12-Monats-Prognose

Durchschnitt 31.6 USD 112.08%

Hoch 40 USD

Tief 27 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.